Clinical Trial Update: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 clinical trial evaluating 225Ac-PSMA-Trillium (BAY 3563254) in patients with advanced metastatic castration-resistant prostate cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 225Ac-PSMA-Trillium (BAY 3563254)

Snippet

Sponsor: Bayer | Conditions: Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression | Phase 1 | Status: RECRUITING